Top

Pavlos Msaouel, M.D., Ph.D.

Department of Genitourinary Medical Oncology, Division of Cancer Medicine

About Dr. Pavlos Msaouel

Dr. Msaouel is a clinician and cancer biologist dedicated to translational research for the treatment of genitourinary malignancies. He received his MD and PhD in cellular and molecular physiology from the University of Athens in Greece. He then completed his internal medicine residency at the Albert Einstein College of Medicine / Jacobi Medical Center, and also served as Chief Resident for the program. He subsequently served as Chief Fellow at MD Anderson Cancer Center while completing his fellowship in medical oncology. His clinical interests are in the treatment of patients with renal cell and urothelial carcinomas, with a particular emphasis on rare variants such as renal medullary carcinoma. His laboratory research focuses on understanding the role of defects in subunits of the SWI/SNF chromatin remodeling complex, such as SMARCB1, in the biology of genitourinary malignancies. His clinical research involves developing and implementing novel clinical trial designs.

Meet Pavlos Msaouel, M.D., Ph.D.

In the News

3D Illustration showing kidneys inside of the body on an imaging scan.

Renal cell carcinoma treatment: What’s new and what's next

2021 class of Andrew Sabin Family Fellows: Francesca Cole, Ph.D.; Michael Curran, Ph.D.; Yejing Ge, Ph.D.; Vivek Subbiah, M.D.; Ching-Wei Tzeng, M.D.; Sangeeta Goswami, M.D., Ph.D.; Betty Y.S. Kim, M.D., Ph.D.; Pavlos Msaouel, M.D., Ph.D.; Michelle Hildebrandt, Ph.D.; Ethan Ludmir, M.D.

MD Anderson announces 2021 class of Andrew Sabin Family Fellows

Present Title & Affiliation

Primary Appointment

Regular Member, Division of Cancer Medicine, UT Houston Graduate School of Biomedical Sciences, Houston, Texas

Assistant Professor (Joint appointment), Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX

Assistant Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Regular Member, The University of Texas Graduate School of Biomedical Sciences, Houston, Texas

Assistant Professor, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX

Assistant Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2011	University of Athens Medical School, Athens, GR, Neoplasm biology, Ph.D
2006	University of Athens Medical School, Athens, GR, MD

Postgraduate Training

2015-2018	Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
2014-2015	Chief Resident, Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, New York, New York
2012-2014	Clinical Residency, Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, New York
2011-2012	Clinical Internship, Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, New York, New York
2007-2009	Research Fellowship, Molecular Medicine, Mayo Clinic, Rochester, Minnesota

Board Certifications

2018	American Board of Internal Medicine - Medical Oncology
2014	American Board of Internal Medicine

Experience & Service

Academic Appointments

Assistant Professor, Albert Einstein College of Medicine, New York, NY, 2014 - 2015

Administrative Appointments/Responsibilities

Evaluation and Management of Suspected ICI-Mediated Pancreatitis and Pancreatic Injury Guidelines Workgroup Member, The University of Texas MD Anderson Cancer Center, Houston, TX, 2024 - Present

Clinical Director of the Prometheus Informatics System, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - Present

Renal Cell Carcinoma Treatment Guidelines Workgroup Member, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present

Urothelial Carcinoma of the Bladder and Upper Tract Treatment Guidelines Workgroup Member, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present

Pharmacy and Therapeutics Committee Member, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - Present

Other Appointments/Responsibilities

Invited Renal Cell Carcinoma Expert, theMednet.org, Online, 2023 - Present

Chief Fellow - Hematology/Medical Oncology Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2018

Clinical Competency Committee Member, Jacobi Medical Center / Albert Einstein College of Medicine; Internal Medicine Residency Program, New York, NY, 2014 - 2015

Leadership Committee Member, Jacobi Medical Center / Albert Einstein College of Medicine; Internal Medicine Residency Program, New York, NY, 2014 - 2015

Chief Resident in Internal Medicine, Jacobi Medical Center / Albert Einstein College of Medicine, New York, NY, 2014 - 2015

Elected Counsillor of the Board of Directors, Hellenic Bioscientific Association in the USA, New York, NY, 2012 - 2014

Chair, Greek Junior Doctors and Health Scientists Society, Athens, 2010 - 2012

Secretary General of the Executive Counsil, Greek Junior Doctors and Health Scientists Society, Athens, 2006 - 2009

Founding Member and Member of the Temporary Executive Counsil, Greek Junior Doctors and Health Scientists Society, Athens, 2003 - 2003

Special Secretary of the Executive Counsil, Greek Junior Doctors and Health Scientists Society, Athens, 2003 - 2005

Elected Student Representative, University of Athens Medical School General Assembly, Athens, 2003 - 2004

Elected Student Representative (Reserve Member), University of Athens Medical School General Assembly, Athens, 2001 - 2003

Institutional Committee Activities

Ad hoc member, Genomic Testing Executive Committee (GTEC), 2025 - Present

Member, Technology Task Force Committee, 2024 - 2027

Member, Odyssey Fellowship Committee, 2024 - Present

Member, Pharmacy and Therapeutics Committee, 2019 - Present

Honors & Awards

2024	2024 Top Performer (perfect score) - ranked nationally by patients in the top 1% of all providers rated in the CGCAHPS survey
2024	R37 MERIT Award, National Institutes of Health / National Cancer Institute
2023	Christopher G. Wood Rising Star Award, Kidney Cancer Association
2022	Translational Research Award, V Foundation
2022	Clinical Trial Grant Award, Gateway for Cancer Research
2021	Advanced Discovery Award, Kidney Cancer Association
2021	Andrew Sabin Family Foundation Fellowship
2021	2021 Top Performer - ranked nationally by patients in the top 10% of all providers rated in the CGCAHPS survey
2021	Physician Scientist Award, The University of Texas MD Anderson Cancer Center
2021	Translational Research Partnership Award, United States Department of Defense
2020	2020 Top Performer - ranked nationally by patients in the top 10% of all providers rated in the CGCAHPS survey
2020	Merit Award, European Society for Medical Oncology
2020	Research Grant Award, KCCure
2019	Next Gen Innovator, HemOnc Today
2019	MD Anderson Khalifa Physician Scientist Award
2019	Top Ranked Abstract - Scientific and Career Development Retreat, American Society of Clinical Oncology - Conquer Cancer Foundation
2019	2019 Top Performer - ranked nationally by patients in the top 10% of all providers rated in the CGCAHPS survey
2019	Awesome Job Award, The University of Texas MD Anderson Cancer Center
2019	Career Development Award, American Society of Clinical Oncology / Conquer Cancer Foundation
2019	Emerging Leader in Health and Medicine Forum, National Academy of Medicine
2018	David A. Swanson, MD, Research Scholar Award, Kidney Cancer Association
2018	Humanitas Award for Compassionate Care of Patients, The University of Texas MD Anderson Cancer Center, Division of Cancer Medicine
2018	Merit Award in Genitourinary Cancers, American Society of Clinical Oncology
2018	Waun Ki Hong Award for Achievement in Basic Science, The University of Texas MD Anderson Cancer Center, Division of Cancer Medicine
2017	The William L. Pippin, Jr Endowed Fellowship in Genitourinary Research
2017	Young Investigator Award, American Society of Clinical Oncology / Kidney Cancer Association
2016	MD Anderson Cancer Center NIH T32 Trainee Award
2016	Clifton D. Howe Award for Clinical Excellence, The University of Texas MD Anderson Cancer Center, Division of Cancer Medicine
2016	Kidney Cancer Association Young Investigator Think Tank, Kidney Cancer Association
2016	Molecular Biology in Clinical Oncology Workshop, American Association for Cancer Research
2014	Best Teaching PGY-3 Resident Award, Jacobi Medical Center / Albert Einstein College of Medicine, Department of Internal Medicine
2014	Induction to the Leo M. Davidoff Society for Outstanding Achievement in the Teaching of Medical Students, Albert Einstein College of Medicine of Yeshiva University
2013	Best Teaching PGY-2 Resident Award, Jacobi Medical Center / Albert Einstein College of Medicine, Department of Internal Medicine
2013	EB-1A Extraordinary Ability Green Card, United States Citizenship and Immigration Services
2012	Best Overall PGY-1 Housestaff Award, Jacobi Medical Center / Albert Einstein College of Medicine, Department of Internal Medicine
2012	Best Quality Improvement & Patient Safety Project, Jacobi Medical Center / Albert Einstein College of Medicine, Department of Internal Medicine
2010	KAPODISTRIAS Fellowship Award, Special Research Account, University of Athens
2009	Travel Grant Award, American Society for Gene and Cell Therapy

Professional Memberships

Kidney Cancer Association

2021 - Present

American Society of Clinical Oncology

2018 - Present

KCCure

2018 - Present

American Association for Cancer Research

2016 - Present

American Medical Association (AMA)

2012 - 2015

American College of Physicians

2011 - 2015

Medical Society of the State of New York

2011 - 2015

American Chemical Society

2010 - 2013

American Society of Gene & Cell Therapy

2008 - 2014

Selected Publications

Peer-Reviewed Articles

Hahn AW, Adra N, Vaishampayan U, Xiao L, Dizman N, Yuan Y, Mukhida SS, Campbell MT, Gao J, Zurita AJ, Jonasch E, Tannir NM, Shah AY, Msaouel P. A phase II trial of sitravatinib + nivolumab after progression on immune checkpoint inhibitor in patients with metastatic clear cell RCC. Oncologist 30(4), 2025. e-Pub 2025. PMID: 40212021.
Sherry AD, Passy AH, Abi Jaoude J, Lin TA, Kouzy R, Msaouel P, Ludmir EB. Treatment group-specific inferences in Phase III Randomized Oncology Trials. Acta Oncol 64:470-474, 2025. e-Pub 2025. PMID: 40126209.
Moussa MJ, Khandelwal J, Wilson NR, Malikayil KL, Surasi DS, Bathala TK, Lin Y, Rao P, Tamboli P, Sircar K, Ajufo H, Elsayes KM, Shah A, Johns AC, Goswami S, Hasanov E, Jonasch E, Msaouel P, Campbell MT, Alhalabi O, Tannir NM. Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma. J Immunother Cancer 13(2), 2025. e-Pub 2025. PMID: 39939142.
Jiwani R, Pal K, Paolucci I, Odisio B, Brock K, Tannir NM, Shapiro DD, Msaouel P, Sheth RA. Differentiating between renal medullary and clear cell renal carcinoma with a machine learning radiomics approach. Oncologist 30(2), 2025. e-Pub 2025. PMID: 39963829.
Grimm SL, Karki M, Blum KA, Bertocchio JP, He R, Tripathi DN, Zacharias NM, Lebenthal JM, Sheth RA, Rao P, Genovese G, Lu Z, Bast RC, Ingram DR, Lazcano R, Wani KM, Wang WL, Lazar AJ, Tannir NM, Walker CL, Coarfa C, Msaouel P. CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation. Clin Cancer Res, 2025. e-Pub 2025. PMID: 39836407.
Sherry AD, Liu Y, Msaouel P, Lin TA, Koong A, Lin C, Jaoude JA, Patel RR, Kouzy R, El-Alam MB, Miller AM, Owiwi M, Ofer J, Bomze D, McCaw ZR, Meirson T, Ludmir EB. Survival-Inferred Fragility of Statistical Significance in Phase III Oncology Trials. medRxiv, 2025. e-Pub 2025. PMID: 39867397.
Msaouel P, Yu K, Yuan Y, Chen J, Yan X, Karki M, Duan F, Sheth RA, Rao P, Sircar K, Shah AY, Zurita AJ, Genovese G, Li M, Yeh CC, Dang M, Han G, Chu Y, Hallin M, Olson P, Yang R, Slavin D, Der-Torossian H, Chin CD, Tannir NM, Wang L, Gao J. Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial. Nat Commun 16(1):578, 2025. e-Pub 2025. PMID: 39794332.
Chahoud J, Msaouel P. Belzutifan for renal cell carcinoma: Balancing regulatory approval with societal and patient impact. Med 6(1):100563, 2025. e-Pub 2025. PMID: 39798548.
Jammihal T, Saliby RM, Labaki C, Soulati H, Gallegos J, Peris A, McCurry D, Yu C, Shah V, Poduval D, El Zarif T, El Ahmar N, Laimon YN, Eid M, Sheshdeh AB, Krajewski KM, Buttner FA, Schwab M, Heng D, Casellas RC, Rai K, Zacharias Millward NM, Msaouel P, Karam J, Signoretti S, Van Allen E, Choueiri TK, Braun DA, Shukla SA. Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma. Nat Cancer, 2025. e-Pub 2025. PMID: 39789182.
Fallara G, Belladelli F, Robesti D, Malavaud B, Tholomier C, Mokkapati S, Montorsi F, Dinney CP, Msaouel P, Martini A. Concomitant antihistamine administration is associated with improved survival outcomes in patients with locally advanced or metastatic urothelial carcinoma treated with atezolizumab. Analysis of individual participant data from IMvigor210 and IMvigor211. Urol Oncol, 2025. e-Pub 2025. PMID: 39788823.
Miller AM, Passy AH, Sherry AD, Kouzy R, Abi Jaoude J, Lin TA, Kupferman GS, Beck EJ, Msaouel P, Ludmir EB. Incomplete Toxicity Reporting and Use of Toxicity-Minimizing Language in Phase III Oncology Trials. JCO Oncol Pract:OP2400735, 2025. e-Pub 2025. PMID: 39778122.
Moussa MJ, Tabet GC, Siefker-Radtke AO, Xiao L, Wilson NR, Gao J, Logothetis CJ, Grivas P, Lee B, Shah AY, Msaouel P, Li R, Clemente LC, Zhao J, Tannir NM, Kamat AM, Hansel DE, Guo CC, Campbell MT, Alhalabi O. Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary Tract. Cancer Med 14(2):e70594, 2025. e-Pub 2025. PMID: 39831734.
Kleber TJ, Sherry AD, Arifin AJ, Kupferman GS, Kouzy R, Jaoude JA, Lin TA, Beck EJ, Miller AM, Passy AH, Mccaw ZR, Msaouel P, Ludmir EB. Justification, margin values, and analysis populations for oncologic noninferiority and equivalence trials: a meta-epidemiological study. J Natl Cancer Inst, 2024. e-Pub 2024. PMID: 39657246.
Moussa MJ, Kovalenko I, Crupi E, Proskuriakova E, Geng Y, Fallara G, Benkhadra R, Raggi D, Campbell MT, Msaouel P, Alhalabi O. Antiangiogenic therapy combined with immune checkpoint blockade in urothelial cancer: Systematic review and meta-analysis. Bladder Cancer 10(4):300-312, 2024. e-Pub 2024. PMID: 40035076.
Graham J, Ahmad AE, Basappa NS, Bernhard JC, Bhindi B, Bosse D, Breau RH, Canil CM, Castonguay V, Finelli A, Heng DYC, Inman BA, Kollmannsberger C, Lalani AA, Lavallee LT, Msaouel P, Prendeville S, Soleimani M, Tanguay S, Wood L, Richard PO, Alimohamed N, Huynh M, Kassouf W, Noonan K, Power N. 2024 CUA-KCRNC Expert Report: Management of non-clear cell renal cell carcinoma. Can Urol Assoc J 18(11):E371-E386, 2024. e-Pub 2024. PMID: 39500366.
Myers AA, Fang AM, Moussa MJ, Hwang H, Wilson NR, Campbell MT, Msaouel P, Lee BH, Guo CC, Zhang M, Zhao J, Siefker-Radtke AO, Kamat AM, Alhalabi O. Impact of systemic therapy on clinical T1 small-cell neuroendocrine carcinoma of the bladder. ESMO Open 9(11):103964, 2024. e-Pub 2024. PMID: 39471563.
Shanker MD, Yu ZH, Yang J, Matin S, Campbell MT, Msaouel P, Tannir N, Prajapati S, Ding Y, Lee B, Sobremonte A, Tang C. MR-Linac-guided stereotactic radiotherapy for CT-indiscernible intravascular renal cell carcinoma tumours. BJUI Compass 5(10):913-915, 2024. e-Pub 2024. PMID: 39416759.
Sherry AD, Msaouel P, Kupferman GS, Lin TA, Abi Jaoude J, Kouzy R, McCaw ZR, Ludmir EB, van Zwet E. Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology. JCO Precis Oncol 8:e2400363, 2024. e-Pub 2024. PMID: 39348660.
Wang E, Rupe ES, Mukhida SS, Johns AC, Campbell MT, Shah AY, Zurita AJ, Gao J, Goswami S, Jonasch E, Msaouel P, Tannir NM, Hahn AW. Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell Carcinoma. Eur Urol Focus, 2024. e-Pub 2024. PMID: 39307587.
Sherry AD, Msaouel P, Ludmir EB. A meta-epidemiological analysis of post-hoc comparisons and primary endpoint interpretability among randomized non-comparative trials in clinical medicine. J Clin Epidemiol:111540, 2024. e-Pub 2024. PMID: 39313076.
Esagian SM, Karam JA, Msaouel P, Makrakis D. Upfront Versus Deferred Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-analysis. Eur Urol Focus, 2024. e-Pub 2024. PMID: 39289076.
Sherry AD, Passy AH, McCaw ZR, Abi Jaoude J, Lin TA, Kouzy R, Miller AM, Kupferman GS, Beck EJ, Msaouel P, Ludmir EB. Increasing Power in Phase III Oncology Trials With Multivariable Regression: An Empirical Assessment of 535 Primary End Point Analyses. JCO Clin Cancer Inform 8:e2400102, 2024. e-Pub 2024. PMID: 39213473.
Campbell MT, Shah AY, Msaouel P, Tannir NM, Siefker-Radtke AO, Kamat AM, Navai N, Dinney CPN, Rao P, Guo CC, Sheth RA, Venkatesan AM, Tidwell RS, Yadav SS, Gu A, Chen H, Macaluso M, Duan F, Basu S, Jindal S, Sharma P. A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle Invasive Bladder Cancer. Cancer Res Commun, 2024. e-Pub 2024. PMID: 39207194.
Sherry AD, Lin TA, McCaw ZR, Beck EJ, Kouzy R, Abi Jaoude J, Passy AH, Miller AM, Kupferman GS, Fuller CD, Thomas CR Jr, Koay EJ, Tang C, Msaouel P, Ludmir EB. Improving the clinical meaning of surrogate endpoints: An empirical assessment of clinical progression in phase III oncology trials. Int J Cancer, 2024. e-Pub 2024. PMID: 39138841.
Beck EJ, Sherry AD, Florez MA, Kouzy R, Abi Jaoude J, Lin TA, Miller AM, Passy AH, Kupferman GS, Patel RR, Chino F, Higbie VS, Parseghian CM, Overman MJ, Minsky BD, Thomas CR, Tang C, Msaouel P, Ludmir EB. Secondary endpoint utilization and publication rate among phase III oncology trials. Cancer Res Commun, 2024. e-Pub 2024. PMID: 39099199.
Sherry AD, Lin TA, McCaw ZR, Beck EJ, Kouzy R, Abi Jaoude J, Passy AH, Miller AM, Kupferman GS, Fuller CD, Thomas CR Jr, Koay EJ, Tang C, Msaouel P, Ludmir EB. Off-Protocol Radiation Therapy in Phase 3 Metastatic Solid Tumor Trials. Int J Radiat Oncol Biol Phys, 2024. e-Pub 2024. PMID: 39352322.
Sherry AD, Msaouel P, Kupferman GS, Lin TA, Abi Jaoude J, Kouzy R, El-Alam MB, Patel R, Koong A, Lin C, Passy AH, Miller AM, Beck EJ, Fuller CD, Meirson T, McCaw ZR, Ludmir EB. Towards Treatment Effect Interpretability: A Bayesian Re-analysis of 194,129 Patient Outcomes Across 230 Oncology Trials. medRxiv, 2024. e-Pub 2024. PMID: 39108512.
Hahn AW, Tidwell RS, Pilie PG, Yu Y, Liu J, Surasi DS, Titus M, Zhang J, Venkatesh N, Panaretakis T, Gregg JR, Zurita AJ, Siddiqui BA, Corn PG, Subudhi SK, Msaouel P, Koutroumpakis E, Huff CD, Aparicio A, McQuade JL, Frigo DE, Logothetis CJ. Body composition as a determinant of the therapeutic index with androgen signaling inhibition. Prostate Cancer Prostatic Dis, 2024. e-Pub 2024. PMID: 39019979.
Lebenthal JM, Kontoyiannis PD, Hahn AW, Lim ZD, Rao P, Cheng JP, Chan B, Daw NC, Sheth RA, Karam JA, Tang C, Tannir NM, Msaouel P. Clinical Characteristics, Management, and Outcomes of Patients with Renal Medullary Carcinoma: A Single-center Retrospective Analysis of 135 Patients. Eur Urol Oncol, 2024. e-Pub 2024. PMID: 39013742.
Moussa MJ, Khandelwal J, Wilson NR, Naik SA, Subbiah V, Campbell MT, Msaouel P, Singh P, Alhalabi O. Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy. Curr Oncol 31(6):3342-3349, 2024. e-Pub 2024. PMID: 38920737.
Sherry AD, Msaouel P, Kouzy R, Abi Jaoude J, Lin TA, Taniguchi CM, Fuller CD, Minsky B, Ludmir EB. Lost in the plot: missing visual elements in Kaplan-Meier plots of phase III oncology trials. Oncologist, 2024. e-Pub 2024. PMID: 38824414.
Sherry, AD, Msaouel, P, Lin, TA, Abi Jaoude, J, Kouzy, R, Beck, EJ, Miller, AM, Passy, AH, Kupferman, GS, Koay, EJ, Fuller, C, Thomas, CR, McCaw, ZR, Ludmir, EB. Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials. BMJ Oncology 3(1), 2024. e-Pub 2024. PMID: 39886131.
Mbilinyi RH, Msaouel P, Rao P, Karam JA, Tannir NM, Tang C. Radiation Therapy for the Management of Renal Medullary Carcinoma: A Multi-Case Study. Clin Genitourin Cancer, 2024. e-Pub 2024. PMID: 38556389.
Sherry AD, Hahn AW, McCaw ZR, Abi Jaoude J, Kouzy R, Lin TA, Minsky B, Fuller CD, Meirson T, Msaouel P, Ludmir EB. Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020. JAMA Netw Open 7(3), 2024. e-Pub 2024. PMID: 38546648.
Johns AC, Campbell MT, Gao M, Hahn AW, Lim Z, Wang E, Gao J, Shah AY, Msaouel P, Tannir NM. Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma. Oncologist, 2024. e-Pub 2024. PMID: 38478923.
Hsu EJ, Lin TA, Dabush DR, McCaw Z, Koong A, Lin C, Abi Jaoude J, Patel R, Kouzy R, El Alam MB, Noticewala S, Yang Y, Sherry AD, Fuller CD, Jr TC, Tang C, Msaouel P, Das P, Huang B, Tian L, Sun R, Lee JJ, Meirson T, Ludmir EB. Association of differential censoring with survival and suboptimal control arms among oncology clinical trials. J Natl Cancer Inst, 2024. e-Pub 2024. PMID: 38331394.
Amara CS, Kami Reddy KR, Yuntao Y, Chan YS, Piyarathna DWB, Dobrolecki LE, Shih DJH, Shi Z, Xu J, Huang S, Ellis MJ, Apolo AB, Ballester LY, Gao J, Hansel DE, Lotan Y, Hodges HC, Lerner SP, Creighton CJ, Sreekumar A, Zheng WJ, Msaouel P, Kavuri SM, Putluri N. The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer. Nat Commun 15(1):1373, 2024. e-Pub 2024. PMID: 38355560.
Msaouel P, Sheth RA. Locoregional Therapies in Immunologically "Cold" Tumors: Opportunities and Clinical Trial Design Considerations. J Vasc Interv Radiol 35(2):198-202, 2024. e-Pub 2024. PMID: 38272640.
Sherry AD, Msaouel P, Lin TA, Abi Jaoude J, Kouzy R, Beck EJ, Miller AM, Passy AH, Kupferman GS, Koay EJ, Fuller CD, Thomas CR, McCaw ZR, Ludmir EB. Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials. BMJ Oncol 3(1):e000322, 2024. e-Pub 2024. PMID: 39886131.
Msaouel P, Lee J, Thall PF. Risk-benefit trade-offs and precision utilities in phase I-II clinical trials. Clin Trials:17407745231214750. e-Pub 2023. PMID: 38111231.
Msaouel P, Sweis RF, Bupathi M, Heath E, Goodman OB, Hoimes CJ, Milowsky MI, Davis N, Kalebasty AR, Picus J, Shaffer D, Mao S, Adra N, Yorio J, Gandhi S, Grivas P, Siefker-Radtke A, Yang R, Latven L, Olson P, Chin CD, Der-Torossian H, Mortazavi A, Iyer G. A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma. Eur Urol Oncol. e-Pub 2023. PMID: 38105142.
Alhalabi O, Wilson N, Xiao L, Lin Y, Khandelwal J, Moussa MJ, Msaouel P, Navai N, Gao J, Kamat AM, Pilie P, Shah AY, Goswami S, Matin S, Kovitz C, Holla V, Guo C, Czerniak B, Logothetis C, Corn PG, Dinney CPN, Campbell MT, Hansel DE, Tannir NM, Siefker-Radtke AO. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol 6(6):611-620, 2023. e-Pub 2023. PMID: 37833193.
Sherry AD, Msaouel P, McCaw ZR, Abi Jaoude J, Hsu EJ, Kouzy R, Patel R, Yang Y, Lin TA, Taniguchi CM, Rödel C, Fokas E, Tang C, Fuller CD, Minsky B, Meirson T, Sun R, Ludmir EB. Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 Fallacy. Eur J Cancer 194:113357, 2023. e-Pub 2023. PMID: 37827064.
Hahn AW, Surasi DS, Viscuse PV, Bathala TK, Wiele AJ, Campbell MT, Zurita AJ, Shah AY, Jonasch E, Gao J, Goswami S, Alhalabi O, Rao P, Sircar K, Tannir NM, Msaouel P. Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy. Oncologist. e-Pub 2023. PMID: 38035767.
Alexandrou M, Driva TS, Makri S, Nikolakea M, Routsi E, Spyrou N, Msaouel P, Esagian SM. Gender disparity trends in genitourinary oncology academic publishing over the past 3 decades: A bibliometric analysis. Urol Oncol 41(10):432.e21-432.e27, 2023. e-Pub 2023. PMID: 37573196.
Iorgulescu JB, Shaw LK, Rashid A, Rao P, Mandayam S, Patel KP, Schmeler KM, Yang RK, Msaouel P. Müllerian-Type Clear Cell Carcinoma of Donor Origin in a Male Patient with a Kidney Transplant: Ascertained by Molecular Testing. Curr Oncol 30(10):9019-9027, 2023. e-Pub 2023. PMID: 37887551.
Lee J, Thall PF, Msaouel P. Bayesian treatment screening and selection using subgroup-specific utilities of response and toxicity. Biometrics 79(3):2458-2473, 2023. e-Pub 2023. PMID: 35974457.
Hahn AW, Kotecha RR, Viscuse PV, Pieretti AC, Wiele AJ, Jonasch E, Lee CH, Gao J, Zurita AJ, Shah AY, Campbell MT, Sharma P, Motzer RJ, Russo P, Wood CG, Tannir NM, Voss MH, Karam JA, Hakimi AA, Msaouel P. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. Eur Urol Focus 9(5):734-741, 2023. e-Pub 2023. PMID: 36863962.
Nze C, Msaouel P, Derbala MH, Stephen B, Abonofal A, Meric-Bernstam F, Tannir NM, Naing A. A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma. Cancers (Basel) 15(15):3806, 2023. e-Pub 2023. PMID: 37568622.
Tan WS, Grajales V, Contieri R, Hensley P, Bree K, Msaouel P, Guo CC, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes. Eur Urol Open Sci 53:16-22, 2023. e-Pub 2023. PMID: 37441349.
Robesti D, Nocera L, Belladelli F, Schultz JG, Fallara G, Marandino L, Raggi D, Montorsi F, Msaouel P, Necchi A, Martini A. The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: Analysis of individual patient data from IMvigor210 and IMvigor211 Trials. BJU Int, 2023. e-Pub 2023. PMID: 37422731.
Perelli L, Carbone F, Zhang L, Huang JK, Le C, Khan H, Citron F, Del Poggetto E, Gutschner T, Tomihara H, Soeung M, Minelli R, Srinivasan S, Peoples M, Lam TNA, Lundgren S, Xia R, Zhu C, Mohamed AMT, Zhang J, Sircar K, Sgambato A, Gao J, Jonasch E, Draetta GF, Futreal A, Bakouny Z, Van Allen EM, Choueiri T, Signoretti S, Msaouel P, Litchfield K, Turajlic S, Wang L, Chen YB, Di Natale RG, Hakimi AA, Giuliani V, Heffernan TP, Viale A, Bristow CA, Tannir NM, Carugo A, Genovese G. Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer. Nat Cancer 4(7):984-1000, 2023. e-Pub 2023. PMID: 37365326.
Vokshi BH, Davidson G, Tawanaie Pour Sedehi N, Helleux A, Rippinger M, Haller AR, Gantzer J, Thouvenin J, Baltzinger P, Bouarich R, Manriquez V, Zaidi S, Rao P, Msaouel P, Su X, Lang H, Tricard T, Lindner V, Surdez D, Kurtz JE, Bourdeaut F, Tannir NM, Davidson I, Malouf GG. SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance. Nat Commun 14(1):3034, 2023. e-Pub 2023. PMID: 37236926.
Soeung M, Perelli L, Chen Z, Dondossola E, Ho IL, Carbone F, Zhang L, Khan H, Le CN, Zhu C, Peoples MD, Feng N, Jiang S, Zacharias NM, Minelli R, Shapiro DD, Deem AK, Gao S, Cheng EH, Lucchetti D, Walker CL, Carugo A, Giuliani V, Heffernan TP, Viale A, Tannir NM, Draetta GF, Msaouel P, Genovese G. SMARCB1 regulates the hypoxic stress response in sickle cell trait. Proc Natl Acad Sci U S A 120(21):e2209639120, 2023. e-Pub 2023. PMID: 37186844.
Alhalabi O, Thouvenin J, Négrier S, Vano YA, Campedel L, Hasanov E, Bakouny Z, Hahn AW, Bilen MA, Msaouel P, Choueiri TK, Viswanathan SR, Sircar K, Albiges L, Malouf GG, Tannir NM. Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas. Oncologist 28(5):433-439, 2023. e-Pub 2023. PMID: 36640141.
Karam JA, Msaouel P, Haymaker CL, Matin SF, Campbell MT, Zurita AJ, Shah AY, Wistuba II, Marmonti E, Duose DY, Parra ER, Soto LMS, Laberiano-Fernandez C, Lozano M, Abraham A, Hallin M, Chin CD, Olson P, Der-Torossian H, Yan X, Tannir NM, Wood CG. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma. Nat Commun 14(1):2684, 2023. e-Pub 2023. PMID: 37164948.
Shapiro DD, Zacharias NM, Tripathi DN, Karki M, Bertocchio JP, Soeung M, He R, Westerman ME, Gao J, Rao P, Lam TNA, Jonasch E, Perelli L, Cheng EH, Carugo A, Heffernan TP, Walker CL, Genovese G, Tannir NM, Karam JA, Msaouel P. Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy. Clin Transl Med 13(5):e1267, 2023. e-Pub 2023. PMID: 37226898.
Alhalabi O, Zhu Y, Hamza A, Qiao W, Lin Y, Wang RM, Shah AY, Campbell MT, Holla V, Kamat A, Wang WL, Wang J, Chen J, Meng J, Zhang M, Bondaruk J, Titus M, Genovese G, Czerniak BA, Shaw KR, Meric-Bernstam F, Guo CC, Logothetis CJ, Siefker-Radtke A, Msaouel P, Wang L, Liu J, Gao J. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol 6(2):228-232, 2023. e-Pub 2023. PMID: 34789422.
Lyman GH, Msaouel P, Kuderer NM. Risk Model Development and Validation in Clinical Oncology: Lessons Learned. Cancer Invest 41(1):1-11, 2023. e-Pub 2023. PMID: 36254812.
Thouvenin J, Alhalabi O, Carlo M, Carril-Ajuria L, Hirsch L, Martinez-Chanza N, Négrier S, Campedel L, Martini D, Borchiellini D, Chahoud J, Lodi M, Barthélémy P, Hasanov E, Hahn AW, Gil T, Viswanathan SR, Bakouny Z, Msaouel P, Asim Bilen M, Choueiri TK, Albiges L, Tannir NM, Malouf GG. Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas. Oncologist 27(12):1041-1047, 2022. e-Pub 2022. PMID: 35979929.
Cao S, Wang JR, Ji S, Yang P, Dai Y, Guo S, Montierth MD, Shen JP, Zhao X, Chen J, Lee JJ, Guerrero PA, Spetsieris N, Engedal N, Taavitsainen S, Yu K, Livingstone J, Bhandari V, Hubert SM, Daw NC, Futreal PA, Efstathiou E, Lim B, Viale A, Zhang J, Nykter M, Czerniak BA, Brown PH, Swanton C, Msaouel P, Maitra A, Kopetz S, Campbell P, Speed TP, Boutros PC, Zhu H, Urbanucci A, Demeulemeester J, Van Loo P, Wang W. Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. Nat Biotechnol 40(11):1624-1633, 2022. e-Pub 2022. PMID: 35697807.
Westerman ME, Bree KK, Msaouel P, Kukreja JB, Mantaring C, Rukundo I, Gonzalez MG, Gregg JR, Casteel KN, Matin SF. Apixaban vs Enoxaparin for Post-Surgical Extended-Duration Venous Thromboembolic Event Prophylaxis: A Prospective Quality Improvement Study. J Urol 208(4):886-895, 2022. e-Pub 2022. PMID: 36082549.
Hahn AW, Lebenthal J, Genovese G, Sircar K, Tannir NM, Msaouel P. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treat Res Commun, 2022. e-Pub 2022. PMID: 36174377.
Lee J, Thall PF, Lim B, Msaouel P. Utility-based Bayesian personalized treatment selection for advanced breast cancer. J R Stat Soc Series C 71(5):1605-1622, 2022. e-Pub 2022. PMID: 36714159.
Msaouel P. The big data paradox in clinical practice. Cancer Invest 40(7):567-576, 2022. e-Pub 2022. PMID: 35671042.
Jimenez-Fonseca P, Salazar R, Valenti V, Msaouel P, Carmona-Bayonas A. Is short-course radiotherapy and total neoadjuvant therapy the new standard of care in locally advanced rectal cancer? A sensitivity analysis of the RAPIDO clinical trial. Ann Oncol 33(8):786-793, 2022. e-Pub 2022. PMID: 35462008.
Msaouel P, Grivas P, Zhang T. Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics. Eur Urol Oncol 5(3):265-267, 2022. e-Pub 2022. PMID: 34561204.
Apolo AB, Msaouel P, Niglio S, Simon N, Chandran E, Maskens D, Perez G, Ballman KV, Weinstock C. Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial Cancers. Am Soc Clin Oncol Educ Book 42:1-16, 2022. e-Pub 2022. PMID: 35609225.
Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, Tam AL, Ahrar K, Rao P, Sircar K, Cohen L, Basu S, Duan F, Jindal S, Zhang Y, Chen H, Yadav SS, Shazer R, Der-Torossian H, Allison JP, Sharma P, Tannir NM. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Science Translational Medicine 14(641), 2022. e-Pub 2022. PMID: 35442707.
Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, Tidwell RS, Han G, Yan X, Meng J, Wang R, Hoang AG, Wang WL, Song J, Lopez L, Andreev-Drakhlin A, Siefker-Radtke A, Zhang X, Benedict WF, Shah AY, Wang J, Msaouel P, Zhang M, Guo CC, Czerniak B, Behrens C, Soto L, Papadimitrakopoulou V, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Roth J, Swisher S, Wistuba I, Heymach J, Wang J, Campbell MT, Efstathiou E, Titus M, Logothetis CJ, Ho TH, Zhang J, Wang L, Gao J. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun 13(1):1797, 2022. e-Pub 2022. PMID: 35379845.
Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Beltran K, Campbell E, Le H, Campbell MT, Shah A, Tannir NM, Siefker-Radtke A, Gao J, Roszik J, Subbiah V. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clin Genitourin Cancer 20(1):e16-e24, 2022. e-Pub 2022. PMID: 34362693.
Valentí V, Jiménez-Fonseca P, Msaouel P, Salazar R, Carmona-Bayonas A. Fooled by randomness. The misleading effect of treatment crossover in randomized trials of therapies with marginal treatment benefit. Cancer Invest 40(2):1-5, 2022. e-Pub 2022. PMID: 34919008.
Carmona-Bayonas A, Jiménez-Fonseca P, Gallego J, Msaouel P. Causal considerations can inform the interpretation of surprising associations in medical registries. Cancer Invest 40(1):1-13, 2022. e-Pub 2022. PMID: 34709109.
Hahn AW, Dizman N, Msaouel P. Missing the trees for the forest: most subgroup analyses using forest plots at the ASCO annual meeting are inconclusive. Ther Adv Med Oncol 14:17588359221103199, 2022. e-Pub 2022. PMID: 35677319.
Tang C, Msaouel P, Hara K, Choi H, Le V, Shah AY, Wang J, Jonasch E, Choi S, Nguyen QN, Das P, Prajapati S, Yu Z, Khan K, Powell S, Murthy R, Sircar K, Tannir NM. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol 22(12):1732-1739, 2021. e-Pub 2021. PMID: 34717797.
Wilson NR, Wiele AJ, Surasi DS, Rao P, Sircar K, Tamboli P, Shah AY, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clin Genitourin Cancer 19(6):e401-e408, 2021. e-Pub 2021. PMID: 34625389.
Shapiro DD, Soeung M, Perelli L, Dondossola E, Surasi DS, Tripathi DN, Bertocchio JP, Carbone F, Starbuck MW, Van Alstine ML, Rao P, Katz MHG, Parker NH, Shah AY, Carugo A, Heffernan TP, Schadler KL, Logothetis C, Walker CL, Wood CG, Karam JA, Draetta GF, Tannir NM, Genovese G, Msaouel P. Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. Cancers (Basel) 13(23), 2021. e-Pub 2021. PMID: 34885132.
Msaouel P. Impervious to Randomness: Confounding and Selection Biases in Randomized Clinical Trials. Cancer Invest 39(10):1-6, 2021. e-Pub 2021. PMID: 34514927.
Lee J, Thall PF, Msaouel P. Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroups. Stat Med 40(24):5199-5217, 2021. e-Pub 2021. PMID: 34636054.
Esagian SM, Khaki AR, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Fröbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Msaouel P, Koshkin VS, Grivas P. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU Int 128(2):196-205, 2021. e-Pub 2021. PMID: 33556233.
Msaouel P, Oromendia C, Siefker-Radtke AO, Tannir NM, Subudhi SK, Gao J, Wang Y, Siddiqui BA, Shah AY, Aparicio AM, Campbell MT, Zurita AJ, Shaw LK, Lopez LP, McCord H, Chakraborty SN, Perales J, Lu C, Van Alstine ML, Elashoff M, Logothetis C. Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Netw Open 4(8):e2122998, 2021. e-Pub 2021. PMID: 34459906.
De B, Venkatesan AM, Msaouel P, Ghia AJ, Li J, Yeboa DN, Nguyen QN, Bishop AJ, Jonasch E, Shah AY, Campbell MT, Wang J, Zurita-Saavedra AJ, Karam JA, Wood CG, Matin SF, Tannir NM, Tang C. Definitive Radiotherapy for Extracranial Oligoprogressive Metastatic Renal Cell Carcinoma as a Strategy to Defer Systemic Therapy Escalation. BJU Int. e-Pub 2021. PMID: 34228889.
Alhalabi O, Hasanov E, Wilson NR, Araujo J, Wang J, Campbell MT, Goswami S, Shah AY, Gao J, Msaouel P, Tannir NM. Outcomes of patients with intermediate- or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. Int J Cancer 149(2):387-393, 2021. e-Pub 2021. PMID: 33739450.
Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer 9(7), 2021. e-Pub 2021. PMID: 34326169.
Wiele AJ, Bathala TK, Hahn AW, Xiao L, Duran M, Ross JA, Jonasch E, Shah AY, Campbell MT, Msaouel P, Tannir NM. Lenvatinib with or without everolimus in patients with metastatic renal cell carcinoma after immune checkpoint inhibitors and VEGFR-TKI therapies. Oncologist 26(6):476-482, 2021. e-Pub 2021. PMID: 33792094.
Wiele AJ, Surasi DS, Rao P, Sircar K, Su X, Bathala TK, Shah AY, Jonasch E, Cataldo VD, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers (Basel) 13(9), 2021. e-Pub 2021. PMID: 33946504.
Karki M, Jangid RK, Anish R, Seervai RNH, Bertocchio JP, Hotta T, Msaouel P, Jung SY, Grimm SL, Coarfa C, Weissman BE, Ohi R, Verhey KJ, Hodges HC, Burggren W, Dere R, Park IY, Prasad BVV, Rathmell WK, Walker CL, Tripathi DN. A cytoskeletal function for PBRM1 reading methylated microtubules. Sci Adv 7(14), 2021. e-Pub 2021. PMID: 33811077.
Laccetti AL, Garmezy B, Xiao L, Economides M, Venkatesan A, Gao J, Jonasch E, Corn P, Zurita-Saavedra A, Brown LC, Kao C, Kinsey EN, Gupta RT, Harrison MR, Armstrong AJ, George DJ, Tannir N, Msaouel P, Shah A, Zhang T, Campbell MT. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Cancer Med 10(7):2341-2349, 2021. e-Pub 2021. PMID: 33650321.
Shaw LK, Wiele AJ, Sircar K, Wood CG, Msaouel P. Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis. Cancer Treatment and Research Communications 27(100349), 2021. e-Pub 2021. PMID: 33725559.
McAtee CL, Lubega J, Underbrink K, Curry K, Msaouel P, Barrow M, Muscal E, Lotze T, Srivaths P, Forbes LR, Allen C, Bernhardt MB. Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults. JAMA Netw Open 4(2):e2036321, 2021. e-Pub 2021. PMID: 33533931.
Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol 39(2):134.e9-134.e16, 2021. e-Pub 2021. PMID: 33187886.
Tomihara H, Carbone F, Perelli L, Huang JK, Soeung M, Rose JL, Robinson FS, Lissanu Deribe Y, Feng N, Takeda M, Inoue A, Poggetto ED, Deem AK, Maitra A, Msaouel P, Tannir NM, Draetta GF, Viale A, Heffernan TP, Bristow CA, Carugo A, Genovese G. Loss of ARID1A promotes epithelial-mesenchymal transition and sensitizes pancreatic tumors to proteotoxic stress. Cancer Res 81(2):332-343, 2021. e-Pub 2021. PMID: 33158812.
Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med 26(12):1845-1851, 2020. e-Pub 2020. PMID: 33046869.
Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes. Mol Cancer Res. e-Pub 2020. PMID: 33323389.
Msaouel P, Genovese G, Gao J, Sen S, Tannir NM. TAM kinase inhibition and immune checkpoint blockade - a winning combination in cancer treatment?. Expert Opin Ther Targets:1-11. e-Pub 2020. PMID: 33356674.
Michalopoulou F, Petraki C, Philippou A, Analitis A, Msaouel P, Koutsilieris M. Expression of IGF-IEc Isoform in Renal Cell Carcinoma Tissues. Anticancer Res 40(11):6213-6219, 2020. e-Pub 2020. PMID: 33109558.
Hahn AW, Alhalabi O, Msaouel P, Meric-Bernstam F, Naing A, Jonasch E, Piha-Paul S, Hong D, Pant S, Yap T, Campbell E, Le H, Tannir NM, Roszik J, Subbiah V. Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open, 2020. e-Pub 2020. PMID: 33229506.
Tannir NM, Msaouel P, Ross JA, Devine CE, Chandramohan A, Gonzalez GMN, Wang X, Wang J, Corn PG, Lim ZD, Pruitt L, Karam JA, Wood CG, Zurita AJ. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial. Eur Urol Oncol 3(5):687-694, 2020. e-Pub 2020. PMID: 31272939.
Bergerot CD, Battle D, Philip EJ, Bergerot PG, Msaouel P, A' S, Bamgboje AE, Shuch B, Derweesh IH, Jonasch E, Stern AP, Pal SK, Staehler M. Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma. JCO Oncol Pract:OP2000105. e-Pub 2020. PMID: 32955409.
Lee J, F Thall P, Msaouel P. A phase I-II design based on periodic and continuous monitoring of disease status and the times to toxicity and death. Stat Med 39(15):2035-2050, 2020. e-Pub 2020. PMID: 32255206.
Msaouel P, Malouf GG, Su X, Yao H, Tripathi DN, Soeung M, Gao J, Rao P, Coarfa C, Creighton CJ, Bertocchio JP, Kunnimalaiyaan S, Multani AS, Blando J, He R, Shapiro DD, Perelli L, Srinivasan S, Carbone F, Pilié PG, Karki M, Seervai RNH, Vokshi BH, Lopez-Terrada D, Cheng EH, Tang X, Lu W, Wistuba II, Thompson TC, Davidson I, Giuliani V, Schlacher K, Carugo A, Heffernan TP, Sharma P, Karam JA, Wood CG, Walker CL, Genovese G, Tannir NM. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell 37:1-15, 2020. e-Pub 2020. PMID: 32359397.
Adashek JJ, Leonard A, Roszik J, Menta AK, Genovese G, Subbiah V, Msaouel P. Cancer Genetics and Therapeutic Opportunities in Urologic Practice. Cancers (Basel) 12(3), 2020. e-Pub 2020. PMID: 32197306.
Xoxakos I, Petraki C, Msaouel P, Armakolas A, Grigorakis A, Stefanakis S, Koutsilieris M. Expression of Kisspeptin (KISS1) and its Receptor GPR54 (KISS1R) in Prostate Cancer. Anticancer Res 40(2):709-718, 2020. e-Pub 2020. PMID: 32014912.
Adashek JJ, Genovese G, Tannir NM, Msaouel P. Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values. Cancer Treat Res Commun 23:100166, 2020. e-Pub 2020. PMID: 31935623.
Zibetti Dal Molin G, Westin SN, Msaouel P, Gomes LM, Dickens A, Coleman RL. Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors. Int J Gynecol Cancer 30(1):89-93, 2020. e-Pub 2020. PMID: 31792084.
Chahoud J, Msaouel P, Campbell MT, Bathala T, Xiao L, Gao J, Zurita AJ, Shah AY, Jonasch E, Sharma P, Tannir NM. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. Oncologist 25(3):252-258, 2020. e-Pub 2020. PMID: 31501271.
Schvartsman G, APCD C, Filippi RZ, Rao P, Msaouel P. Rapid Deep Responses With Nivolumab Plus Ipilimumab in Papillary Renal Cell Carcinoma With Sarcomatoid Dedifferentiation. Clin Genitourin Cancer 17(4):315-318, 2019. e-Pub 2019. PMID: 31213412.
Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, Xiao L, Gao J, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer 114:67-75, 2019. e-Pub 2019. PMID: 31075726.
Alevizakos M, Gaitanidis A, Nasioudis D, Msaouel P, Appleman LJ. Sarcomatoid Renal Cell Carcinoma: Population-Based Study of 879 Patients. Clin Genitourin Cancer 17(3):e447-e453, 2019. e-Pub 2019. PMID: 30799129.
Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clin Genitourin Cancer 17(1):1-6, 2019. e-Pub 2019. PMID: 30287223.
Carugo A, Minelli R, Sapio L, Soeung M, Carbone F, Robinson FS, Tepper J, Chen Z, Lovisa S, Svelto M, Amin S, Srinivasan S, Del Poggetto E, Loponte S, Puca F, Dey P, Malouf GG, Su X, Li L, Lopez-Terrada D, Rakheja D, Lazar AJ, Netto GJ, Rao P, Sgambato A, Maitra A, Tripathi DN, Walker CL, Karam JA, Heffernan TP, Viale A, Roberts CWM, Msaouel P, Tannir NM, Draetta GF, Genovese G. p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell 35(2):204-220, 2019. e-Pub 2019. PMID: 30753823.
Campbell MT, Bilen MA, Shah AY, Lemke E, Jonasch E, Venkatesan AM, Altinmakas E, Duran C, Msaouel P, Tannir NM. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. Eur J Cancer 104:188-194, 2018. e-Pub 2018. PMID: 30380460.
Msaouel P, Tannir NM, Walker CL. A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma. Clin Cancer Res 24(9):2044-2049, 2018. e-Pub 2018. PMID: 29440190.
Msaouel P, Opyrchal M, Dispenzieri A, Peng KW, Federspiel MJ, Russell SJ, Galanis E. Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets 18(2):177-187, 2018. e-Pub 2018. PMID: 28228086.
Lontos K, Tsagianni A, Msaouel P, Appleman LJ, Nasioudis D. Primary Urinary Tract Lymphoma: Rare but Aggressive. Anticancer Res 37(12):6989-6995, 2017. e-Pub 2017. PMID: 29187485.
Keskin SK, Msaouel P, Hess KR, Yu KJ, Matin SF, Sircar K, Tamboli P, Jonasch E, Wood CG, Karam JA, Tannir NM. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. J Urol 198(3):530-537, 2017. e-Pub 2017. PMID: 28411072.
Msaouel P, Gralla RJ, Jones RA, Hollen PJ. Key issues affecting quality of life and patient-reported outcomes in prostate cancer: an analysis conducted in 2128 patients with initial psychometric assessment of the prostate cancer symptom scale (PCSS). BMJ Support Palliat Care 7(3):308-315, 2017. e-Pub 2017. PMID: 28167656.
Holzhauser L, Hovnanians N, Eshtehardi P, Mojadidi MK, Deng Y, Goodman-Meza D, Msaouel P, Ko YA, Zolty R. Statin therapy improves survival in patients with severe pulmonary hypertension: a propensity score matching study. Heart Vessels 32(8):969-976, 2017. e-Pub 2017. PMID: 28303379.
Maiti A, Nemati-Shafaee M, Msaouel P, Pagliaro LC, Jonasch E, Tannir NM, Shah AY. Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. Clin Genitourin Cancer, 2017. e-Pub 2017. PMID: 28870517.
Msaouel P, Zurita AJ, Huang S, Jonasch E, Tannir NM. Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma. Oncotarget 8(26):42149-42158, 2017. e-Pub 2017. PMID: 28178674.
Msaouel P, Malouf GG, Tannir NM. Linking Gene Mutations to Clinical Outcomes and Response to Therapy in Clear-cell Renal Cell Carcinoma: Ready for Prime Time?. Eur Urol 71(3):415-416, 2017. e-Pub 2017. PMID: 27816301.
Msaouel P, Bilen MA, Zhang M, Campbell M, Wang J, Tu SM. Recent developments in the management of germ cell tumors. Curr Opin Oncol, 2017. e-Pub 2017. PMID: 28151756.
Mantzaris I, Yu Y, Msaouel P, Lam AP, Janakiram M, Friedman EW, Steidl U, Verma AK. Analysis of overall survival in a large multiethnic cohort reveals absolute neutrophil count of 1,100 as a novel prognostic cutoff in African Americans. Oncotarget 7(42):67948-67955, 2016. e-Pub 2016. PMID: 27144332.
Mojadidi MK, Galeas JN, Goodman-Meza D, Eshtehardi P, Msaouel P, Kelesidis I, Zaman MO, Winoker JS, Roberts SC, Christia P, Zolty R. Thrombocytopaenia as a Prognostic Indicator in Heart Failure with Reduced Ejection Fraction. Heart Lung Circ 25(6):568-75, 2016. e-Pub 2016. PMID: 26868831.
Otusanya O, Goraya H, Iyer P, Landi K, Tibb A, Msaouel P. A vicious cycle of acute catecholamine cardiomyopathy and circulatory collapse secondary to pheochromocytoma. Oxf Med Case Reports 2015(10):343-5, 2015. e-Pub 2015. PMID: 26512333.
Sidlow R, Msaouel P. Improving Hepatitis C Virus Screening Rates in Primary Care: A Targeted Intervention Using the Electronic Health Record. J Healthc Qual 37(5):319-23, 2015. e-Pub 2015. PMID: 26186704.
Hollen PJ, Msaouel P, Gralla RJ. Determining issues of importance for the evaluation of quality of life and patient-reported outcomes in breast cancer: results of a survey of 1072 patients. Breast Cancer Res Treat 151(3):679-86, 2015. e-Pub 2015. PMID: 25981897.
Savvidis C, Papaoiconomou E, Petraki C, Msaouel P, Koutsilieris M. The role of KISS1/KISS1R system in tumor growth and invasion of differentiated thyroid cancer. Anticancer Res 35(2):819-26, 2015. e-Pub 2015. PMID: 25667462.
Armakolas A, Kaparelou M, Dimakakos A, Papageorgiou E, Armakolas N, Antonopoulos A, Petraki C, Lekarakou M, Lelovas P, Stathaki M, Psarros C, Donta I, Galanos PS, Msaouel P, Gorgoulis VG, Koutsilieris M. Oncogenic Role of the Ec Peptide of the IGF-1Ec Isoform in Prostate Cancer. Mol Med 21:167-79, 2015. e-Pub 2015. PMID: 25569803.
Msaouel P, Kappos T, Tasoulis A, Apostolopoulos AP, Lekkas I, Tripodaki ES, Keramaris NC. Comparison of resident performance in interpreting mammography results using a probabilistic or a natural frequency presentation: a multi-institutional randomized experimental study. Educ Health (Abingdon) 28(1):29-34, 2015. e-Pub 2015. PMID: 26261111.
Leotsakos I, Dimopoulos P, Gkioka E, Msaouel P, Nezos A, Stravodimos KG, Koutsilieris M, Constantinides CA. Detection of circulating tumor cells in bladder cancer using multiplex PCR assays. Anticancer Res 34(12):7415-24, 2014. e-Pub 2014. PMID: 25503182.
Mojadidi MK, Goodman-Meza D, Eshtehardi P, Pamerla M, Msaouel P, Roberts SC, Winoker JS, Jadeja NM, Zolty R. Thrombocytopenia is an independent predictor of mortality in pulmonary hypertension. Heart Lung 43(6):569-73, 2014. e-Pub 2014. PMID: 25169667.
Domingo-Musibay E, Allen C, Kurokawa C, Hardcastle JJ, Aderca I, Msaouel P, Bansal A, Jiang H, DeGrado TR, Galanis E. Measles Edmonston vaccine strain derivatives have potent oncolytic activity against osteosarcoma. Cancer Gene Ther 21(11):483-90, 2014. e-Pub 2014. PMID: 25394505.
Mojadidi MK, Winoker JS, Roberts SC, Msaouel P, Zaman MO, Gevorgyan R, Tobis JM. Accuracy of conventional transthoracic echocardiography for the diagnosis of intracardiac right-to-left shunt: a meta-analysis of prospective studies. Echocardiography 31(9):1036-48, 2014. e-Pub 2014. PMID: 24689727.
Gralla RJ, Hollen PJ, Msaouel P, Davis BV, Petersen J. An evidence-based determination of issues affecting quality of life and patient-reported outcomes in lung cancer: results of a survey of 660 patients. J Thorac Oncol 9(9):1243-8, 2014. e-Pub 2014. PMID: 25122420.
Salamon JN, Kelesidis I, Msaouel P, Mazurek JA, Mannem S, Adzic A, Zolty R. Outcomes in World Health Organization group II pulmonary hypertension: mortality and readmission trends with systolic and preserved ejection fraction-induced pulmonary hypertension. J Card Fail 20(7):467-75, 2014. e-Pub 2014. PMID: 24858070.
Karavitakis M, Msaouel P, Michalopoulos V, Koutsilieris M. Pattern of somatostatin receptors expression in normal and bladder cancer tissue samples. Anticancer Res 34(6):2937-42, 2014. e-Pub 2014. PMID: 24922657.
Mojadidi MK, Winoker JS, Roberts SC, Msaouel P, Gevorgyan R, Zolty R. Two-dimensional echocardiography using second harmonic imaging for the diagnosis of intracardiac right-to-left shunt: a meta-analysis of prospective studies. Int J Cardiovasc Imaging 30(5):911-23, 2014. e-Pub 2014. PMID: 24740212.
Msaouel P, Lam AP, Gundabolu K, Chrysofakis G, Yu Y, Mantzaris I, Friedman E, Verma A. Abnormal platelet count is an independent predictor of mortality in the elderly and is influenced by ethnicity. Haematologica 99(5):930-6, 2014. e-Pub 2014. PMID: 24510340.
Papaoiconomou E, Lymperi M, Petraki C, Philippou A, Msaouel P, Michalopoulou F, Kafiri G, Vassilakos G, Zografos G, Koutsilieris M. Kiss-1/GPR54 protein expression in breast cancer. Anticancer Res 34(3):1401-7, 2014. e-Pub 2014. PMID: 24596387.
Msaouel P, Kappos T, Tasoulis A, Apostolopoulos AP, Lekkas I, Tripodaki ES, Keramaris NC. Assessment of cognitive biases and biostatistics knowledge of medical residents: a multicenter, cross-sectional questionnaire study. Med Educ Online 19:23646, 2014. e-Pub 2014. PMID: 24646439.
Opyrchal M, Allen C, Msaouel P, Iankov I, Galanis E. Inhibition of Rho-associated coiled-coil-forming kinase increases efficacy of measles virotherapy. Cancer Gene Ther 20(11):630-7, 2013. e-Pub 2013. PMID: 24157925.
Lam AP, Gundabolu K, Sridharan A, Jain R, Msaouel P, Chrysofakis G, Yu Y, Friedman E, Price E, Schrier S, Verma AK. Multiplicative interaction between mean corpuscular volume and red cell distribution width in predicting mortality of elderly patients with and without anemia. Am J Hematol 88(11):E245-9, 2013. e-Pub 2013. PMID: 23828763.
Karakou E, Glynos C, Samara KD, Msaouel P, Koutsilieris M, Vassilakopoulos T. Profile of endocrinological derangements affecting PSA values in patients with COPD. In Vivo 27(5):641-9, 2013. e-Pub 2013. PMID: 23988900.
Savvani A, Petraki C, Msaouel P, Diamanti E, Xoxakos I, Koutsilieris M. IGF-IEc expression is associated with advanced clinical and pathological stage of prostate cancer. Anticancer Res 33(6):2441-5, 2013. e-Pub 2013. PMID: 23749893.
Evangelou I, Petraki C, Msaouel P, Scorilas A, Sdrolia E, Padazi G, Koborozos V, Koutsilieris M. Immunohistochemical expression of somatostatin receptor subtypes 2 and 5 in colorectal cancer. Eur J Clin Invest 42(7):777-83, 2012. e-Pub 2012. PMID: 22304674.
Makri A, Msaouel P, Petraki C, Milingos D, Protopapas A, Liapi A, Antsaklis A, Magkou C, Koutsilieris M. KISS1/KISS1R expression in eutopic and ectopic endometrium of women suffering from endometriosis. In Vivo 26(1):119-27, 2012. e-Pub 2012. PMID: 22210725.
Msaouel P, Iankov ID, Allen C, Russell SJ, Galanis E. Oncolytic measles virus retargeting by ligand display. Methods Mol Biol 797:141-62, 2012. e-Pub 2012. PMID: 21948475.
Msaouel P, Keramaris NC, Apostolopoulos AP, Syrmos N, Kappos T, Tasoulis A, Tripodaki ES, Kagiampaki E, Lekkas I, Siegrist J. The effort-reward imbalance questionnaire in Greek: translation, validation and psychometric properties in health professionals. J Occup Health 54(2):119-30, 2012. e-Pub 2012. PMID: 22313863.
Msaouel P, Opyrchal M, Galanis E. Translational research in oncolytic measles virotherapy: early discoveries and future steps. Future Microbiol 6(2):125-8, 2011. e-Pub 2011. PMID: 21366411.
Iankov ID, Msaouel P, Allen C, Federspiel MJ, Bulur PA, Dietz AB, Gastineau D, Ikeda Y, Ingle JN, Russell SJ, Galanis E. Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. Breast Cancer Res Treat 122(3):745-54, 2010. e-Pub 2010. PMID: 19894113.
Msaouel P, Keramaris NC, Tasoulis A, Kolokythas D, Syrmos N, Pararas N, Thireos E, Lionis C. Burnout and training satisfaction of medical residents in Greece: will the European Work Time Directive make a difference?. Hum Resour Health 8:16, 2010. e-Pub 2010. PMID: 20594310.
Msaouel P, Iankov ID, Allen C, Aderca I, Federspiel MJ, Tindall DJ, Morris JC, Koutsilieris M, Russell SJ, Galanis E. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol Ther 17(12):2041-8, 2009. e-Pub 2009. PMID: 19773744.
Msaouel P, Iankov ID, Allen C, Morris JC, von Messling V, Cattaneo R, Koutsilieris M, Russell SJ, Galanis E. Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate 69(1):82-91, 2009. e-Pub 2009. PMID: 18973133.
Pikoulis E, Msaouel P, Avgerinos ED, Anagnostopoulou S, Tsigris C. Evolution of medical education in ancient Greece. Chin Med J (Engl) 121(21):2202-6, 2008. e-Pub 2008. PMID: 19080185.
Plastira K, Msaouel P, Angelopoulou R, Zanioti K, Plastiras A, Pothos A, Bolaris S, Paparisteidis N, Mantas D. The effects of age on DNA fragmentation, chromatin packaging and conventional semen parameters in spermatozoa of oligoasthenoteratozoospermic patients. J Assist Reprod Genet 24(10):437-43, 2007. e-Pub 2007. PMID: 17768675.
Lyrakou S, Mantas D, Msaouel P, Baathalah S, Shrivastav P, Chrisostomou M, Mihalopoulos Y, Hasiakos D, Baka S. Crossover analysis using immunofluorescent detection of MLH1 foci in frozen-thawed testicular tissue. Reprod Biomed Online 15(1):99-105, 2007. e-Pub 2007. PMID: 17623546.
Plastira K, Angelopoulou R, Mantas D, Msaouel P, Lyrakou S, Plastiras A, Bolaris S, Baka S, Paparisteidis N. The effects of age on the incidence of aneuploidy rates in spermatozoa of oligoasthenozoospermic patients and its relationship with ICSI outcome. Int J Androl 30(2):65-72, 2007. e-Pub 2007. PMID: 17073945.
Mantas D, Angelopoulou R, Msaouel P, Plastira K. Evaluation of sperm chromatin quality and screening of Y chromosome microdeletions in Greek males with severe oligozoospermia. Arch Androl 53(1):5-8, 2007. e-Pub 2007. PMID: 17364456.
Lembessis P, Msaouel P, Halapas A, Sourla A, Panteleakou Z, Pissimissis N, Milathianakis C, Bogdanos J, Papaioannou A, Maragoudakis E, Dardoufas C, Dimopoulos T, Koutsilieris M. Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy. Clin Chem Lab Med 45(11):1488-94, 2007. e-Pub 2007. PMID: 17924845.
Avgerinos ED, Msaouel P, Koussidis GA, Keramaris NC, Bessas Z, Gourgoulianis K. Greek medical students' career choices indicate strong tendency towards specialization and training abroad. Health Policy 79(1):101-6, 2006. e-Pub 2006. PMID: 16413630.
Mantas D, Msaouel P, Angelopoulou R. Evaluation of gram stain as an alternative in the assessment of human spermatozoa quality. Urol Int 76(1):57-62, 2006. e-Pub 2006. PMID: 16401922.

Manuals, Teaching Aids, Other Teaching Publications

Msaouel P. "Endocrine Oncology" In: Encyclopedia of Cancer. Springer, 2016.

Editorials

Shapiro DD, Msaouel P. Challenges and Considerations in Modern Adjuvant Therapy Trials in Renal Cell Carcinoma: A Call to Power. Eur Urol, 2024. PMID: 39472204.
Shapiro DD, Msaouel P. Adjuvant therapy for renal cell carcinoma: Finding the signal in the noise. Urol Oncol, 2024. PMID: 39003109.
Tang C, Msaouel P. Charting the Path to Systemic Therapy De-escalation-Oligometastatic Kidney Cancer as a Paradigm. JAMA Oncol, 2024. PMID: 38451536.
Msaouel P. The Role of Sampling in Medicine. Harvard Data Science Review 5(3), 2023.
Msaouel P. Less is More? First Impressions from COSMIC-313. Cancer Invest 41(1):101-106, 2023. PMID: 36239611.
Msaouel P, Jimenez-Fonseca P, Lim B, Carmona-Bayonas A, Agnelli G. Medicine before and after David Cox. Eur J Intern Med 98:1-3, 2022. PMID: 35241350.
Alhalabi O, Msaouel P. Truncating CDKN1A mutations: an insight into the biology of urinary tract carcinomas?. Am J Cancer Res 11(2):6214-6217, 2021. PMID: 35018253.
Msaouel P, Walker CL, Genovese G, Tannir NM. Molecular hallmarks of renal medullary carcinoma: more to c-MYC than meets the eye. Mol Cell Oncol 7(5):1777060, 2020. PMID: 32944636.
Msaouel P, Carugo A, Genovese G. Targeting proteostasis and autophagy in SMARCB1-deficient malignancies: where next?. Oncotarget 10(40):3979-3981, 2019. PMID: 31258836.
Msaouel P, Malouf GG, Tannir NM. Metabolic Derangements in Succinate Dehydrogenase B–Mutated Renal-Cell Carcinomas: More Than Meets the Eye?. JCO Precision Oncology(1):1-4, 2017.
Malouf GG, Msaouel P, Khayat D, Tannir NM. Using Mutations of Epigenetic Regulators and Genetic Evolution to Select Therapies for Genitourinary Malignancies: The Road to Ithaca. Genitourinary Cancer Symposium, 2016.
Msaouel P, Galanis E. Measles virotherapy in prostate cancer treatment: a novel antitumor approach. Future Virology 4(3):203-207, 2009.

Abstracts

Staehler MD, Vaishampayan U, Pal SK, Msaouel P, Derweesh I, Penson DF, Battle DJ. Financial toxicity in non-metastatic versus metastatic renal cell carcinoma patients 211(5S), 2024. e-Pub 2024.
Tang C, Hara K, Sherry AD, Serrano AG, Kostousov LV, Hernandez SD, Lu W, Shen L, Shah AY, Jonasch E, Karam JA, Matin SF, Tannir N, Wang J, Msaouel P, Sircar K, Solis L. YIA24-001: Spatial Evolution of Immune Cell Dysfunction During Development of Oligometastatic Renal Cell Carcinoma: Secondary Analysis of a Prospective Trial. J Natl Compr Canc Netw 22(2.5), 2024. e-Pub 2024. PMID: 38579843.
Shanker M, Yu H, Yang J, Matin SF, Campbell MT, Msaouel P, Tannir NM, Prajapati S, Tang C. MR-Linac Guided Motion-Adaptive Stereotactic Radiotherapy for the Treatment of CT-Indiscernible Intravascular Renal Cell Carcinoma Tumors. 2023 RSS Scientific Meeting, 2023. e-Pub 2023.
Hara K, Corredor-Alonso GE, Serrano AG, Hernandez SD, Lu W, Shah AY, Jonasch E, Karam JA, Matin SF, Tannir NM, Msaouel P, Sircar K, Solis LM, Tang C. Evaluation of immune exhaustion across the evolution of oligometastatic clear cell renal cell carcinoma using spatially resolved tissue immune profiling: Secondary analysis of a prospective trial. Journal of Clinical Oncology, 2023. e-Pub 2023.
Shapiro D, Zacharias NM, Tripathi D, Bertocchio JP, Soeung M, Rao P, Walker CL, Genovese G, Tannir NM, Wood C, Karam J, Msaouel P. Combining neddylation inhibition with chemotherapy to treat renal medullary carcinoma. Journal of Urology, 2021. e-Pub 2021.
Shapiro DD, Millward Zacharias N, Tripathi DN, Bertocchio JP, Soeung M, Rao P, Walker CL, Genovese G, Tannir NM, Wood CG, Karam JA, Msaouel P. Targeting neddylation in combination with cytotoxic chemotherapy for the treatment of renal medullary carcinoma. Cancer Research 81(13), 2021. e-Pub 2021.
Pant S, Shah A, Msaouel P, Campbell M, Shi-Ming T, Gao JJ, Blumenschein G, Mott F, Le X, Altan M, Meric-Bernstam F, Yap T, Subbiah V, Rodon J, Glasmacher A, Mulder I, Chisamore M, Stevenson A, Tannir NM. Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs). Journal for ImmunoTherapy of Cancer 8, 2020. e-Pub 2020.
Alhalabi O, Hasanov E, Araujo J, Wang J, Campbell M, Goswami S, Shah AY, Gao JJ, Msaouel P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with intermediate- or poor-risk symptomatic disease who received their first cycle of nivolumab and ipilimumab while being hospitalized. Journal for ImmunoTherapy of Cancer 8, 2020. e-Pub 2020.
Matulay J, Campbell MT, Narayan V, Seif M, Lim A, Shah A, Msaouel P, Gao JJ, Siefker-Radtke A, Dinney C, Kamat AM, Navai N. Pathologic outcomes after neoadjuvant chemotherapy for high-risk muscle invasive bladder cancer. European Society For Medical Oncology (ESMO) Congress 2019, 2019. e-Pub 2019.
Msaouel P, Slack-Tidwell R, Tannir NM. Phase II trial of nivolumab (nivo) plus ipilimumab (ipi) in patients with SMARCB1-deficient kidney malignancies. Journal of Clinical Oncology 37(7S):TPS677, 2019. e-Pub 2019.
Laccetti AL, Economides MP, Venkatesan AM, Gao JJ, Jonasch E, Corn PG, Zurita AJ, Tannir NM, Msaouel P, Shah AY, Campbell MT. Combination anti-angiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Journal of Clinical Oncology 37(7S):630, 2019. e-Pub 2019.
Msaouel P, Slack-Tidwell R, Genovese G, Daw NC, Siefker-Radtke AO, Tannir NM. Phase II trial of ixazomib combined with gemcitabine and doxorubicin in patients with SMARCB1-deficient kidney malignancies. Journal of Clinical Oncology 37(7S):TPS678, 2019. e-Pub 2019.
Shah AY, Kotecha R, Lemke E, Chandramohan A, Chaim J, P <, Xiao L, Gao JJ, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM. Outcomes of patients with metastatic clear cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Journal of Clinical Oncology 37(7S):575, 2019. e-Pub 2019.

Book Chapters

Ross JA, Msaouel P, Tannir NM. Management of Non-Clear Cell Renal Cell Carcinoma. In: Renal Cancer: Contemporary Management. Springer, 307-323, 2020.
Msaouel P, Rao P, Tannir NM. Renal Medullary Carcinoma. In: Rare Kidney Tumors: Comprehensive Multidisciplinary Management and Emerging Therapies. 1st. Springer, 65-76, 2019.
Msaouel P, Galanis E. Oncolytic Measles Virus-based delivery systems. In: Gene and Cell Therapy: Therapeutic Mechanisms and Strategies. 4th Edition. CRC Press, 157-174, 2014.
Souliotis KN, Keramaris NC, Msaouel P. Catastrophic Health Care Expenditures and Inequalities in Access to Health Care Services in Greece. In: Oncolytic Viruses: Methods and Protocols. Papazissis Publishers, 215-219, 2009.

Letters to the Editor

Sherry AD, Ludmir EB, Msaouel P. Sunitinib for the treatment of phaeochromocytomas and paragangliomas. Lancet 405: 380-381, 2025.

Less

Selected Presentations & Talks

Local Presentations

2025. Recent Advances in the Management of Rare and Common Advanced Kidney Cancers. Invited. Department of Investigational Cancer Therapeutics Journal Club. Houston, Texas, US.
2023. Retiring Statistical Significance: But What Next?. Conference. Retiring Statistical Significance: But What Next?. Houston, TX, US.
2023. Reconstructing Statistics as an Information Science: Clinical and Translational Implications. Conference. Reconstructing Statistics as an Information Science: Clinical and Translational Implications. Houston, TX, US.
2023. The Big Data Paradox and its Implications in Rare Cancer Research. Conference. The Big Data Paradox and its Implications in Rare Cancer Research. Houston, TX, US.

National Presentations

2025. How to Interpret Randomized Clinical Trials. Invited. Lecture Series of the Academy of Kidney Cancer Investigators and Kidney Cancer Association Mentorship Academy. Houston, Texas, US.
2024. HIF2α Inhibitors in the Management of Kidney Cancer. Conference. Genitourinary Pathology Society Virtual Education Series, US.
2024. Principles of Randomization in Experiments: Random Sampling vs. Random Allocation. Conference. Biostatistics and Bioinformatics Café. Houston, TX, US.
2024. Unraveling the Unique Connection Between Exercise Intensity and Renal Medullary Carcinoma Risk. Invited. XVI Annual Weinman Symposium. Honolulu, Hawaii, US.
2024. Myeloid Mimicry Drives Hyperprogression to Immunotherapy in Renal Medullary Carcinoma. Conference. Research Town Hall. Houston, TX, US.
2023. The paradox of big data. Conference. 6th Global Summit on Genitourinary Malignancies. Colorado Springs, CO, US.
2023. Moelcularly targeted therapy for medullary renal cell carcinoma. Conference. 6th Global Summit on Genitourinary Malignancies. Colorado Springs, CO, US.
2023. Renal cell carcinoma subtypes as models of distinct oncometabolic hallmarks. Conference. Research Town Hall. Houston, TX, US.
2023. Causal Inference and the Relevance-Robustness Trade-off in Medicine. Conference. Health Services Department Seminar. Houston, TX, US.
2023. Rare Kidney Cancers. Conference. 2nd Annual Regional Symposium. Chicago, IL, US.
2023. Retiring Statistical Significance: But What Next?. Conference. Emil J Freireich Leukemia Hematology Grand Rounds. Houston, TX, US.
2023. Reconstructing Statistics as an Information Science: Clinical and Translational Implications. Conference. Stem Cell Transplant Department Meeting. Houston, TX, US.
2023. The Big Data Paradox and its Implications in Rare Cancer Research. Conference. Sarcoma Medical Oncology - Seminar Series. Houston, TX, US.
2023. Locoregional Therapies in Immunologically "Cold" Tumors: Opportunities and Clinical Trial Design Considerations. Conference. Society for Interventional Radiology 2023 Annual Meeting. Phoenix, AZ, US.
2022. Hypoxia drives tumorigenesis and therapy resistance in renal medullary carcinoma. Conference. Hypoxia drives tumorigenesis and therapy resistance in renal medullary carcinoma. Philadelphia, PA, US.
2021. The future of adjuvant therapy for high-risk non-metastatic renal cell carcinoma. Conference. 22nd Annual Meeting of the Society of Urologic Oncology. Orlando, FL, US.
2021. Distinct Genomic And Immune Hallmarks Of Renal Medullary Carcinoma. Conference. 2021 Annual Meeting of the Society for Basic Urologic Research. Orlando, FL, US.
2021. Renal Medullary Carcinoma Pathogenesis. Conference. Kidney Cancer Research Summit 2021. Philadelphia, PA, US.
2021. Electronically Enabled Monitoring of Immune Toxicity Using the Ronin Platform. Conference. IOTOX Research Retreat. Houston, TX, US.
2021. Renal Medullary Carcinoma. Conference. Sickle Cell Trait 360. Houston, TX, US.
2020. Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma; Samuel’s Lectureship Closed Session. Conference. 23rd Annual Samuels Lectureship. Houston, TX, US.
2020. Comprehensive Molecular Profiling of Renal Medullary Carcinoma Reveals Synthetic Vulnerabilities to Stress Responses. Conference. Cancer Epigenetics: New Mechanisms and Therapeutic Opportunities. Keystone, CO, US.
2019. Comprehensive Molecular Profiling Reveals Distinct Hallmarks of Renal Medullary Carcinoma. Conference. Cell Symposia: Hallmarks of Cancer. Seattle, WA, US.
2019. Sitravatinib in combination with nivolumab demonstrates clinical Activity in platinum-experienced patients with urothelial carcinoma who progressed on prior checkpoint inhibitor. Conference. 34th Annual Meeting of the Society for Immunotherapy of Cancer. National Harbor, MD, US.
2019. Novel Mechanism of Pathogenesis for Renal Medullary Carcinoma. Conference. Kidney Cancer Research Summit 2019. Philadelphia, PA, US.
2019. The role of clinical investigation and clinical trials in therapeutic development. Conference. 2019 Emerging Leaders in Health and Medicine Forum. Washington, DC, DC, US.
2019. TAM Family Members in IO. Conference. Exelixis. Houston, TX, US.
2019. Management of Targeted Therapy and Immunotherapy Toxicities. Conference. Pfizer. Houston, TX, US.
2019. New Targets in Renal Medullary Carcinoma. Conference. New Targets in Renal Medullary Carcinoma. Houston, TX, US.
2018. Systemic treatment options for patients with metastatic non-clear cell renal cell carcinoma. Conference. 2018 Kidney Cancer Patient and Caregiver Conference. Chicago, IL, US.
2017. Unraveling the role of epigenetic deregulation in renal medullary carcinoma. Conference. Workshop on Integrative Next-gen Epigenomics. Houston, TX, US.
2017. Translational Lab Research Updates on Renal Medullary Carcinoma. Conference. Inaugural Renal Medullary Carcinoma Alliance Meeting. Washington, DC, US.
2015. Evaluation of a Practical Low-Cost Quality Intervention to Improve Adherence to Evidence-Based Cancer Screening Recommendations in 642 Patients. Conference. The American College of Physicians (ACP) Internal Medicine Meeting. Boston, MA, US.
2009. Optimizing the Antitumor Activity of Engineered Measles Virus Strains in the Treatment of Gliomas. Conference. 12th Annual Meeting of the American Society of Gene & Cell Therapy. San Diego, CA, US.
2009. In Vivo Image-Guided Radiovirotherapy for Prostate Cancer Using an Engineered Measles Virus Encoding the Thyroidal Sodium Iodide Symporter. Conference. 12th Annual Meeting of the American Society of Gene & Cell Therapy. San Diego, CA, US.
2008. Oncolytic measles virus derivatives have significant antitumor activity against prostate cancer. Conference. 11th Annual Meeting of the American Society of Gene & Cell Therapy. Boston, MA, US.
2008. Oncolytic Measles Virus Strains Are Effective Therapy for Malignant Pleural Effusions in a Xenograft Model of Advanced Breast Cancer. Conference. 11th Annual Meeting of the American Society of Gene & Cell Therapy. Boston, MA, US.

International Presentations

2025. Turning the Tide: How We Doubled the Survival of Patients with Renal Medullary Carcinoma. Invited. Enjoy Science Webinar Series. Houston, US.
2025. How to Interpret Randomized Clinical Trials. Invited. U-COPE Ukraine Clinical Oncology Project ECHO, UA.
2024. Treatment strategies for advanced non-clear cell renal cell carcinomas. Invited. 17th Annual Meeting of the Korean Society of Medical Oncology & 2024 International Conference. Seoul, KR.
2024. Variant Histology RCC: Contemporary Management and How to Move the Field Forward. Conference. 13th Canadian Kidney Cancer Forum. Toronto, CA.
2024. Causal Inference Methodology in Kidney Cancer Research. Conference. 13th Canadian Kidney Cancer Forum. Toronto, CA.
2024. Renal medullary carcinoma. Conference. Controversies in Genitourinary Tumors. Milano, IT.
2023. Structural causal modeling in oncology. Conference. 2023 International Kidney Cancer Symposium: North America. Nashville, US.
2023. Patient-Centric Research and Practice for Rare and Common Malignancies. Conference. 2023 Scientific and Career Development Retreat. Alexandria, US.
2023. The big data paradox in clinical practice. Conference. 49th Annual Panhellenic Medical Conference. Athens, GR.
2023. Patient-centered systemic therapy decisions in urologic malignancies. Conference. Postgraduate course of Athens Medical Center. Athens, GR.
2021. First-line and sequence of treatments in metastatic kidney cancer. Conference. 4th Symposium of Oncological Urology, CO.
2021. Zodiac does not influence survival in advanced stomach cancer. Conference. Congress of the Spanish Society of Medical Oncology (SEOM). Madrid, ES.
2020. Bioinformatics and virtual clinical studies. Conference. Innovation in Oncology Seminar. Athens, GR.
2020. Targeting Synthetic Vulnerabilities in Renal Medullary Carcinoma. Conference. 19th International Kidney Cancer Symposium, US.
2020. A Phase I/II trial of sitravatinib (sitra) combined with Nivolumab (nivo) in patients with advanced clear cell renal cell cancer (aCCRCC) that progressed on prior VEGF-targeted therapy. Conference. American Society of Clinical Oncology (ASCO). San Francisco, US.
2019. Changing paradigms in statistical interpretation: do we still need the p-value?. Conference. 18th International Kidney Cancer Symposium. Miami, US.
2019. Comprehensive Molecular Profiling of Renal Medullary Carcinoma Reveals Synthetic Vulnerabilities of SMARCB1-deficient malignancies to Stress Responses. Conference. 2019 Scientific and Career Development Retreat. Alexandria, US.
2019. Phase II trial of nivolumab (nivo) plus ipilimumab (ipi) in patients with SMARCB1-deficient kidney malignancies. Conference. 2019 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO). San Francisco, US.
2019. Phase II trial of ixazomib combined with gemcitabine and doxorubicin in patients with SMARCB1-deficient kidney malignancies. Conference. 2019 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASC0). San Francisco, US.
2018. Comparative transcriptomic profiling of renal medullary carcinoma (RMC) to determine distinct signatures and pathways associated with response to chemotherapy. Conference. 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, US.
2018. Effect of SMARCB1 deficiency in renal medullary carcinoma (RMC) on genes associated with nucleosome assembly and telomere organization. Conference. 2018 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO). San Francisco, US.
2018. A phase I/II study of sitravatinib (MGCD-516) plus nivolumab in patients (pts) with metastatic clear-cell renal cell carcinoma (ccRCC) that progressed on prior VEGF-targeted therapy. Conference. 2018 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO). San Francisco, US.
2018. Comparing cabozantinib (C) treatment for a cohort of patients with metastatic clear cell (ccRCC) and variant histology renal cell carcinoma (vhRCC): A retrospective study. Conference. 2018 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO). San Francisco, US.
2017. Renal Medullary Carcinoma. Conference. 16th International Kidney Cancer Symposium. Miami, US.
2017. Outcomes of patients with renal cell carcinoma and sarcomatoid dedifferentiation treated with nephrectomy and systemic therapies over three decades: The MD Anderson Cancer Center experience. Conference. 2017 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO). Orlando, US.
2015. Establishing a new quality of life (QL) / patient reported outcome (PRO) / symptom scale in advanced cancer: Content validity for the "CSS" based on input from 3860 patients. Conference. 51st annual meeting of the American Society of Clinical Oncology (ASCO). Chicago, US.
2014. Improving clinical prognostic categories beyond performance status: Enhancing accuracy in survival prediction with a three-item patient-reported outcome (PRO) index from the LCSS in lung cancer and mesothelioma. Conference. 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, US.
2014. Accuracy of Two-Dimensional Echocardiography using Second Harmonic Imaging for the Diagnosis of Intracardiac Right-to-Left Shunt: A Meta-Analysis of Prospective Studies. Conference. The International Stroke Conference. San Diego, US.
2007. The role of immune mechanism in the etiopathology of postpartum depression (csf and plasma cytokine levels). Conference. 1st Eastern European Congress of Psychiatry. Thessaloniki, GR.
2007. CSF and plasma cytokine levels at delivery and postpartum depression. Conference. 9th Psychoimmunology Expert Meeting Neuropsychoimmunology of Psychosis. Günzburg, DE.
2006. Correlation of apoptosis and aneuploidy in spermatozoa of oligoasthenozoospermic patients. Conference. 4th International European Congress of Andrology and 23rd Congress of the French-Speaking Society of Andrology. Toulouse, FR.
2003. Deletions of the Y chromosome in infertile men. Conference. International Congress of Anthropology "Homo Sapiens Past, Present and Future". Paleoanthropology and modern human populations of Eastern Mediterranean. Athens, GR.
2003. Pleistocene violence as a possible interpretation of the double skull burial at the cave site of Apidima, South Peloponnese, Greece. Conference. International Congress of Anthropology "Homo Sapiens Past, Present and Future". Paleoanthropology and modern human populations of Eastern Mediterranean. Athens, GR.
2003. Sperm oxidative damage and the role of reactive oxygen species in male infertility. Conference. International Congress of Anthropology "Homo Sapiens Past, Present and Future". Paleoanthropology and modern human populations of Eastern Mediterranean. Athens, GR.

Formal Peers

2025. Turning the Tide: How we Doubled the Survival of Patients with Renal Medullary Carcinoma - Grand Rounds Lecture. Tucson, Arizona, US.
2025. Renal Medullary Carcinoma as a Paradigm for Accelerating Discovery in Rare and Common Pediatric Diseases. Houston, Texas, US.
2025. Renal Medullary Carcinoma: Discovery and Validation of Tailored Treatment Strategies - Grand Rounds Lecture. Houston, Texas, US.
2025. Cracking the Code: How we Integrated Data Science and Biology to Double Renal Medullary Carcinoma Survival - Grand Rounds Lecture. Houston, Texas, US.
2025. Turning the Tide: How We Doubled the Survival of Patients with Renal Medullary Carcinoma. Houston, Texas, US.
2025. Leading Clinical Research Faculty Learning Series. Houston, Texas, US.
2024. Relevant and Robust Data Science Frameworks for Bench-to-Bedside Research: Lessons from Kidney Cancer. Invited. Relevant and Robust Data Science Frameworks for Bench-to-Bedside Research: Lessons from Kidney Cancer. Boston, MA, US.
2024. Reconstructing Statistics as an Information Science: Clinical and Translational Implications. Invited. Reconstructing Statistics as an Information Science: Clinical and Translational Implications. Bethesda, MD, US.
2023. Renal Medullary Carcinoma: Bench-to-Bedside - Grand Rounds Lecture. Invited. Renal Medullary Carcinoma: Bench-to-Bedside - Grand Rounds Lecture. New York City, NY, US.
2023. Data-driven Elucidation of Renal Medullary Carcinoma Pathogenesis Using Structural Causal Modeling. Invited. Data-driven Elucidation of Renal Medullary Carcinoma Pathogenesis Using Structural Causal Modeling. Houston, TX, US.
2023. Applying Translational Research Principles in the Therapeutic Decision Process - Grand Rounds Lecture. Invited. Applying Translational Research Principles in the Therapeutic Decision Process - Grand Rounds Lecture. Houston, TX, US.
2022. Statistics in Clinical Decision Making: Common Pitfalls - Grand Rounds Lecture Series. Invited. Statistics in Clinical Decision Making: Common Pitfalls - Grand Rounds Lecture Series. New Orleans, LA, US.
2022. Renal Medullary Carcinoma. Invited. Renal Medullary Carcinoma. New York City, NY, US.
2022. Renal Medullary Carcinoma: Bench to Bedside - Grand Rounds Lecture. Invited. Renal Medullary Carcinoma: Bench to Bedside - Grand Rounds Lecture. Houston, TX, US.
2022. Renal Medullary Carcinoma: Bench to Bedside - Grand Rounds Lecture. Invited. Renal Medullary Carcinoma: Bench to Bedside - Grand Rounds Lecture. Seattle, WA, US.
2021. Renal Medullary Carcinoma - Grand Rounds Lecture. Invited. Renal Medullary Carcinoma - Grand Rounds Lecture. Boston, MA, US.
2021. Renal Medullary Carcinoma - Grand Rounds Lecture. Invited. Renal Medullary Carcinoma - Grand Rounds Lecture. Newark, DE, US.
2021. Random Musings on RCTs and how to (not) Interpret them. Invited. Random Musings on RCTs and how to (not) Interpret them. Sao Paolo, BR.
2021. Statistics in Clinical Decision Making: Common Pitfalls. Invited. Statistics in Clinical Decision Making: Common Pitfalls. Sao Paolo, BR.
2021. Renal Medullary Carcinoma - Grand Rounds Lecture. Invited. Renal Medullary Carcinoma - Grand Rounds Lecture. New York City, NY, US.
2021. Confounding and Causal Inference. Invited. Confounding and Causal Inference. Houston, TX, US.
2019. When c-Met inhibitors and urothelial carcinoma meet: early evidence for clinical activity. Visiting. When c-Met inhibitors and urothelial carcinoma meet: early evidence for clinical activity. Houston, TX, US.
2019. What is the best first-line systemic therapy for favorable-risk clear-cell RCC? Answer: A sequential therapy of VEGFR-TKI followed by immune checkpoint inhibitor(s). Visiting. What is the best first-line systemic therapy for favorable-risk clear-cell RCC? Answer: A sequential therapy of VEGFR-TKI followed by immune checkpoint inhibitor(s). Houston, TX, US.
2019. Statistics in Clinical and Translational Research: Common Pitfalls. Invited. Statistics in Clinical and Translational Research: Common Pitfalls. Houston, TX, US.
2018. Cabozantinib is the best salvage therapy after failure of immune checkpoint inhibition. Visiting. Cabozantinib is the best salvage therapy after failure of immune checkpoint inhibition. Houston, TX, US.
2018. Systemic Therapy for Metastatic Non-Clear Cell Histology Patients: What Works and What Doesn’t?. Visiting. Systemic Therapy for Metastatic Non-Clear Cell Histology Patients: What Works and What Doesn’t?. Houston, TX, US.

Less

Grant & Contract Support

Date:	2025 - 2029
Title:	Functional and Clonal Characterization of the Extinction of HIF Signaling in VHL-Driven Renal Cancers
Funding Source:	DOD-PRMRP-IIRA
Role:	Co-I
ID:	PR240492

Date:	2024 - 2027
Title:	Targeting Myeloid Mimicry in Renal Medullary Carcinoma
Funding Source:	DOD
Role:	PI
ID:	RA230062

Date:	2024 - 2028
Title:	Identification of Novel Antigens for Development of T Cell-Based Therapies in Renal Medullary Carcinoma
Funding Source:	DOD-KCRP-Idea
Role:	PI
ID:	KC230210P2

Date:	2024 - 2028
Title:	Immunotherapy-Induced Cellular Plasticity and Metastatic Organotropism in Renal Medullary Carcinoma
Funding Source:	DOD-KCRP-Idea
Role:	PI
ID:	KC230139P1

Date:	2024 - 2029
Title:	Elucidating T Cell Ferroptosis in Renal Medullary Carcinoma: 3D Genome Architecture Rewiring and Therapeutic Alleviation
Funding Source:	NIH/NCI
Role:	PI
ID:	CA285454-01A1

Date:	2024 - 2029
Title:	Mechanisms of Hyperprogression to Immunotherapy in SMARCB1-Deficient Renal Malignancies
Funding Source:	NIH/NCI
Role:	PI
ID:	R01 CA288448-01

Date:	2023 - 2026
Title:	Evaluation of Tumor Frameshift Neoantigens as a Novel Circulating Bioanalyte during Radiation Therapy for Oligometastatic Clear Cell Renal Cell Carcinoma
Funding Source:	Department of Defense (DOD)
Role:	Collaborator
ID:	KC220078

Date:	2023 - 2028
Title:	Tumor Frameshift Neoantigens Mediating Immunotherapy Response in Renal Cell Carcinoma
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	CA282063-01

Date:	2023 - 2026
Title:	Targeting Distinct Metabolic Vulnerabilities of Aggressive Renal Cell Carcinoma Variants
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	RP230271

Date:	2023 - 2026
Title:	Provoking the Immunotherapy Efficacy of Renal Medullary Carcinoma
Funding Source:	Department of Defense (DOD)
Role:	Co-Mentor
ID:	KC220138

Date:	2023 - 2025
Title:	Phase II Trial of Relatlimab plus Nivolumab in Renal Medullary Carcinoma
Funding Source:	Gateway for Cancer Research
Role:	PI
ID:	G-23-300

Date:	2022 - 2025
Title:	Evolution of Individual Patient’s Tumor Immune Microenvironment in the Development of Clear Cell Renal Cell Carcinoma
Funding Source:	Department of Defense (DOD)
Role:	Collaborator
ID:	KC210009

Date:	2022 - 2025
Title:	Define a novel class of frameshift neoantigens that mediate and predict response to immune checkpoint therapy in renal cell carcinoma
Funding Source:	The V Foundation
Role:	Co-PI

Date:	2022 - 2025
Title:	Harnessing Cancer-Specific Frameshift Neoantigens for the Early Detection of Renal Medullary Carcinoma
Funding Source:	The V Foundation
Role:	PI
ID:	T2022-011

Date:	2022 - 2027
Title:	A Novel Frameshift Neoantigen-Based Biomarker that Accurately Predicts Clinical Response to Immune Checkpoint Therapy in Patients with Renal Cell Carcinoma
Funding Source:	NIH/NCI
Role:	PI
ID:	CA269588

Date:	2022 - 2026
Title:	A Phase I Trial of Personalized Neoantigen Cancer Vaccine Therapy in Combination with Nivolumab and Ipilimumab for Metastatic Clear Cell Renal Cell Carcinoma
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP220398

Date:	2022 - 2025
Title:	Define a Novel Class of Frameshift Neoantigens that Mediate and Predict Response to Immune Checkpoint Therapy in Renal Cell Carcinoma
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	RP220213

Date:	2021 - 2024
Title:	Identification of Tumor Frameshift Neoantigens to Accurately Predict Response to Immune Checkpoint Therapy in Renal Cell Carcinoma
Funding Source:	Kidney Cancer Association (KCA)
Role:	Co-PI

Date:	2021 - 2024
Title:	Targeting resistance mechanisms in SMARCB1-deficient tumors
Funding Source:	Department of Defense (DOD)
Role:	Co-PI
ID:	KC200096P1

Date:	2021 - 2023
Title:	Targeting Resistance Mechanisms in Renal Medullary Carcinoma
Funding Source:	Andrew Sabin Family Foundation Fellowship
Role:	PI

Date:	2020 - 2021
Title:	Integrative Epigenetic Profiling of Regulatory Networks Driving Renal Medullary Carcinoma
Funding Source:	The Kidney Cancer Research Alliance
Role:	PI

Date:	2019 - 2021
Title:	Targeting p53-mediated resistance in SMARCB1-deficient malignancies to identify novel therapeutic strategies targeting SMARCB1 loss particularly in SMARCB1-deficient malignancies that develop resistance to drugs targeting the proteostatic machinery by bypassing the p53 checkpoint
Funding Source:	UT MD Anderson Cancer Center-Khalifa Scholars Program
Role:	PI
ID:	Khalifa Physician-Scientist Award

Date:	2019 - 2022
Title:	Targeting synthetic vulnerabilities induced by stress responses in SMARCB1-deficient malignancies
Funding Source:	American Society of Clinical Oncology (ASCO)
Role:	PI

Date:	2018 - 2020
Title:	A Novel Mechanism of Pathogenesis for Renal Medullary Carcinoma
Funding Source:	Department of Defense (DOD)
Role:	PI
ID:	KC170062

Date:	2018 - 2019
Title:	Guanine Deaminase as a Novel Biomarker of Response to Microtubule-Targeting Agents in Renal Cell Carcinomas
Funding Source:	Kidney Cancer Association
Role:	Young Investigator
ID:	Young Investigator Award

Date:	2017 - 2018
Title:	Targeting the EZH2-STAT3 Pathway in Renal Medullary Carcinoma
Funding Source:	American Society of Clinical Oncology (ASCO)
Role:	Young Investigator
ID:	Conquer Cancer Foundation Young Investigator Award

Date:	2017 - 2020
Title:	Phase I/II Trial of MGCD516 Combined with Nivolumab in Patients with Advanced Clear Cell Renal Cell Cancer that Progressed on Prior VEGF-Targeted Therapy
Funding Source:	Gateway for Cancer Research Grant No. G-17-600
Role:	Co-PI

Date:	2007 - 2009
Title:	Engineered Measles Virus as a Novel Oncolytic Therapy for Prostate Cancer
Funding Source:	Mayo Clinic Prostate Specialized Program of Research Excellence (SPORE) Grant
Role:	Collaborator
ID:	P50091956

CV information above last modified April 16, 2025

Pavlos Msaouel, M.D., Ph.D.

About Dr. Pavlos Msaouel

In the News

Renal cell carcinoma treatment: What’s new and what's next

MD Anderson announces 2021 class of Andrew Sabin Family Fellows

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Manuals, Teaching Aids, Other Teaching Publications

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Selected Presentations & Talks

Local Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Related Links

Kidney Cancer

Genitourinary Cancer Center

Genitourinary Medical Oncology Department

Cancer Medicine Division

Help #EndCancer

Pavlos Msaouel, M.D., Ph.D.

About Dr. Pavlos Msaouel

In the News

Renal cell carcinoma treatment: What’s new and what's next

MD Anderson announces 2021 class of Andrew Sabin Family Fellows

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Manuals, Teaching Aids, Other Teaching Publications

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Selected Presentations & Talks

Local Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Kidney Cancer

Genitourinary Cancer Center

Genitourinary Medical Oncology Department

Cancer Medicine Division

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer